"We are very pleased about our investment in Veran, which allows the company to execute and drive adoption of its products," said Greg Johnson, managing director at Prolog Ventures. "There is no doubt that early detection and treatment is the key to cancer care. Veran's products intend to fill a very critical need in medicine today. We believe that Veran's products will be instrumental in improving the efficacy of therapies for certain diseases such as lung cancer."
"We believe the value of Veran's product line is unique because it provides benefits for patients, physicians, hospitals and ultimately taxpayers," said Jeremy R. Degenhart, senior vice president at Advantage Capital Partners.
About Veran Medical Technologies, Inc.
Veran Medical Technologies is a privately held image-guided medical device company focused on developing the next standard of care for minimally invasive delivery of interventional oncology therapies. Veran provides proprietary 4D registration capability for precise targeting of lesions via its FDA cleared platform. The Veran platform aims to reduce procedure times and increase accuracy, enabling clinicians to cost effectively treat patients with reduced co-morbidity risk. Veran Medical Technologies relocated from Nashville, Tennessee to St. Louis, Missouri.
|SOURCE Veran Medical Technologies|
Copyright©2008 PR Newswire.
All rights reserved